The activation of angiotensin II type 1 receptor (AT1R) and subsequent events involving MAPK p44/42 (also known as ERK1/2) and JNK (c-Jun N-terminal kinase) signaling pathways can have significant implications for various clinical diseases, including those with potential links to Alzheimer’s disease (AD), such as hypertension and cardiovascular diseases, diabetes mellitus and diabetic complications, neuroinflammatory conditions or stroke, and ischemic injury [15]. Here, MAPK3 is linked to Alzheimer disease.